Cytosorbents Corporation
CTSO
$1.13
$0.000.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.58% | 5.03% | 3.56% | -7.69% | 8.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.58% | 5.03% | 3.56% | -7.69% | 8.62% |
| Cost of Revenue | 28.24% | -0.31% | -19.49% | -7.61% | -28.70% |
| Gross Profit | -5.80% | 8.04% | 20.44% | -7.74% | 55.00% |
| SG&A Expenses | -13.99% | -7.55% | 1.26% | 18.68% | -3.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.12% | -17.74% | -15.16% | 12.91% | -6.72% |
| Operating Income | 39.56% | 50.54% | 37.59% | -44.36% | 20.52% |
| Income Before Tax | 74.61% | 32.67% | 13.21% | -257.70% | 24.65% |
| Income Tax Expenses | -- | -- | -- | 25.53% | -- |
| Earnings from Continuing Operations | 74.61% | 32.67% | 13.21% | -661.64% | 24.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.61% | 32.67% | 13.21% | -661.64% | 24.65% |
| EBIT | 39.56% | 50.54% | 37.59% | -44.36% | 20.52% |
| EBITDA | 41.58% | 53.83% | 40.68% | -43.14% | 23.22% |
| EPS Basic | 79.30% | 45.42% | 30.11% | -611.93% | 25.95% |
| Normalized Basic EPS | 79.43% | 47.65% | 30.15% | -250.63% | 27.44% |
| EPS Diluted | 79.30% | 45.42% | 30.11% | -611.93% | 25.95% |
| Normalized Diluted EPS | 79.43% | 47.65% | 30.15% | -250.63% | 27.44% |
| Average Basic Shares Outstanding | 22.71% | 23.38% | 24.24% | 6.68% | 1.76% |
| Average Diluted Shares Outstanding | 22.71% | 23.38% | 24.24% | 6.68% | 1.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
